Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Microba Life Sciences Limited ( (AU:MAP) ) is now available.
Microba Life Sciences reported strong operational progress for the half year to 31 December 2025, with 10,258 core tests sold globally, a 113% increase on the prior period, and an annualised run rate above 21,300 tests as it targets more than 24,000 tests in FY26. Growth was driven by record adoption of Microbiome Explorer in Australia, rapid uptake in the United Kingdom where it now accounts for all GI tests sold, and steady MetaPanel adoption, while all legacy products have been discontinued.
The company completed a major brand and laboratory consolidation, introduced AI tools to lift efficiency, released new product features to support high-volume clinician use, and expects more than $1 million in cost savings over 24 months alongside $2 million in annual staff cost reductions. Although total revenue fell 9% to $7.32 million due to legacy product exit, core testing and growth product revenue more than doubled, the therapeutics portfolio has moved into an active partnering phase, and management says Microba remains on track to reach regional break-even by the end of FY26, strengthening its position in an emerging diagnostic category.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.29 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is an ASX-listed precision microbiome company focused on improving human health through advanced gut microbiome testing and related diagnostics. Its core offerings include the Microbiome Explorer test for clinicians and patients, MetaPanel in partnership with Sonic Healthcare, and a growing presence in the U.K. gastrointestinal testing and supplements market.
Average Trading Volume: 414,182
Technical Sentiment Signal: Hold
Current Market Cap: A$52.98M
For a thorough assessment of MAP stock, go to TipRanks’ Stock Analysis page.